Bmi1在前列腺癌中的表达及临床意义

doi:10.3969/j.issn.1006-7795.2016.03.013

首都医科大学学报 ›› 2016, Vol. 37 ›› Issue (3): 323-326.doi: 10.3969/j.issn.1006-7795.2016.03.013

• 前列腺癌发病机制与临床治疗研究 • 上一篇下一篇

Bmi1在前列腺癌中的表达及临床意义

林云华¹, 姜永光¹, 方微², 王俊生¹, 周绍酉³, 孙秀梅⁴

1. 首都医科大学附属北京安贞医院泌尿科, 北京 100029;
2. 首都医科大学附属北京安贞医院病理科, 北京 100029;
3. 首都医科大学2011级临床五年2班, 北京 100069;
4. 首都医科大学2011级临床七年班, 北京 100069

收稿日期:2016-04-06 出版日期:2016-06-21 发布日期:2016-06-13
通讯作者: 林云华 E-mail:scalpel@163.com
基金资助:
北京市卫生系统高层次卫生技术人才基金(2013-2-003),2014年首都医科大学本科生科研创新课题(XSKY2014112)。

Expression of Bmi1 in prostate cancer and its clinical implication

Lin Yunhua¹, Jiang Yongguang¹, Fang Wei², Wang Junsheng¹, Zhou Shaoyou³, Sun Xiumei⁴

1. Department of Urology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China;
2. Department of Pathology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China;
3. Class 2, Grade 2011, School of Medicine, Capital Medical University, Beijing 100069, China;
4. Class of Seven-year Program, Grade 2011, School of Medicine, Capital Medical University, Beijing 100069, China

Received:2016-04-06 Online:2016-06-21 Published:2016-06-13
Supported by:
This study was supported by Beijing Health System High Level Health Technical Personnel (2013-2-003), 2014 Undergraduate Research Innovation Subject of Capital Medical University (XSKY2014112).

摘要/Abstract

摘要： 目的探讨Bmi1蛋白在前列腺癌中的表达及临床意义。方法应用免疫组织化学方法对前列腺癌(65例)和良性前列腺增生(15例)标本中Bmi1蛋白表达进行检测,将Bmi1染色结果与临床病理参数进行对照研究。结果 Bmi1在前列腺癌组织中的表达较良性增生组织明显增加(P <0.01);Bmi1的表达与Gleason评分具有相关性(P <0.01),与危险分级(P=0.013)相关,与前列腺癌复发进展相关(P <0.05),但Bmi1表达和前列腺特异性抗原(prostate specific antigen,PSA)浓度之间无明显的相关性。结论 Bmi1蛋白在前列腺癌组织中的表达增加,其表达与肿瘤的低分化、高风险和不良预后明显相关。

关键词: Bmi1, 前列腺癌, 免疫组织化学

Abstract: Objective To investigate the expression and significance of Bmi1 protein in prostate cancer (PC).Methods We used immunohistochemistry to study the expression of the Bmi1 protein in PC (n=65) and benign prostate hypertrophy (BPH) (n=15) specimens. The Bmi1 staining scores were compared with several clinicopathological parameters.Results Compared with the BPH specimens, the expression of Bmi1 increased in PC epithelium (P <0.01). The expression of Bmi1 was associated with high Gleason scores (P <0.01), pre-treatment risk stratification (P=0.013), and recurrence or progression (P <0.05) of PC patients. There was no statistically significant association between Bmi1 expression and serum prostate specific antigen (PSA) level. Conclusion The expression of Bmi1 was increased in PC specimens and was associated with poor differentiation, high risk and poor prognosis of the cancer.

Key words: Bmi1, prostate cancer, immunohistochemistry

中图分类号:

林云华, 姜永光, 方微, 王俊生, 周绍酉, 孙秀梅. Bmi1在前列腺癌中的表达及临床意义[J]. 首都医科大学学报, 2016, 37(3): 323-326.

Lin Yunhua, Jiang Yongguang, Fang Wei, Wang Junsheng, Zhou Shaoyou, Sun Xiumei. Expression of Bmi1 in prostate cancer and its clinical implication[J]. Journal of Capital Medical University, 2016, 37(3): 323-326.

参考文献

[1] Siegel R, Naishadham D, Jemal A. Cancer statistics[J]. CA Cancer J Clin, 2012, 62(1):10-29.
[2] Haupt Y, Alexander W S, Barri G, et al. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice[J]. Cell, 1991, 65(5): 753-763.
[3] Van Lohuizen M, Verbeek S, Scheijen B, et al. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging[J]. Cell, 1991, 65(5): 737-752.
[4] Liu S, Dontu G, Mantle I D, et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells[J]. Cancer Res, 2006, 66(12): 6063-6071.
[5] Lukacs R U, Memarzadeh S, Wu H, et al. Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation[J]. Cell Stem Cell, 2010, 7(6):682-693.
[6] Crea F, Duhagon Serrat M A, Hurt E M, et al. BMI1 silencing enhances docetaxelactivity and impairs antioxidant response in prostate cancer[J]. Int J Cancer,2011, 128(8) :1946-1954.
[7] Nacerddine K, Beaudry J B, Ginjala V, et al. Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer[J]. J Clin Invest, 2012, 122(5):1920-1932.
[8] Haupt Y, Alexander W S, Barri G, et al. Novel zinc finger gene implicated as myc collaborator by retovirally accelerated lymphomagenesis in Emu-myc transgenic mice [J]. Cell, 1991, 65(5): 753-763.
[9] Van Lohuizen M, Frasch M, Wientjens E, et al. Sequence similarity between the mammalian bmi-1 proto-oncogene and the Drosophila regulatory genes Psc and Su(z)2 [J]. Nature,1991,353 (6342):353-355.
[10] Jiang L, Li J, Song L. Bmi-1,stem cell and cancer[J]. Acta Biochim Biophys Sin(Shanghai),2009, 41(7): 527-534.
[11] Park I K, Morrison S J, Clarke M F. Bmi-1, stem cells, and senescence regulation[J]. J Clin Invest, 2004,113(2):175-179.
[12] Dimri G P,Marlinez J L,Jacobs J J,et al.The Bmi1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells[J].Cancer Res, 2002, 62(16):4736-4745.
[13] Pun J C, Chan J Y, Chun B K,et al.Plasma Bmi1 mRNA as a potential prognostic biomarker for distant metastasis in colorectal cancer patients[J]. Mol Clin Oncol, 2014,2(5): 817-820.
[14] Vonlanthen S,Heighway J,Altermatt H J,et al. The Bmi1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A／ARF locus expression [J]. Br J Cancer, 2001,84(10):1372-1376.
[15] Wang H,Pan K,Zhang H K,et al.Increased polycomb group oncogene Bmi1 expression correlates with poor prognosis in hepatocellular carcinoma[J].J Cancer Res Clin Oncol, 2008,134(5):535-541.
[16] 曹希亮, 高江平. 晚期前列腺癌药物治疗研究进展[J]. 解放军医药杂志,2013,25(2):59-63.
[17] 李小攀, 杨琛,孙乔,等. 2002-2013年上海市浦东新区居民前列腺癌发病死亡趋势分析[J]. 中华肿瘤防治杂志,2015,22(6):412-415.
[18] Siddique H R, Parray A, Zhong W, et al. BMI1, stem cell factor acting as novel serum-biomarker for caucasian and African-American prostate cancer[J]. PLoS One, 2013, 8(1): e52993.

Bmi1在前列腺癌中的表达及临床意义

Expression of Bmi1 in prostate cancer and its clinical implication

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李颖, 陈彪, 王乃利, 郝欣平. 人体内耳冰冻切片免疫组织化学染色技术探讨[J]. 首都医科大学学报, 2022, 43(6): 905-910.
[2]	赵越, 阮祥燕, 程姣姣, 谷牧青, 许新, 王月姣. 乳腺癌中PGRMC1表达与临床病理参数的相关性[J]. 首都医科大学学报, 2022, 43(3): 350-356.
[3]	蒋铭心, 苏瑶, 熊天宇, 叶小波, 靳松, 邢念增, 金木兰, 杨敏福, 牛亦农. 减瘤性根治性前列腺切除术对骨转移前列腺癌患者的临床疗效分析[J]. 首都医科大学学报, 2021, 42(6): 967-972.
[4]	王明帅, 熊天宇, 蒋铭心, 钱小松, 王思豪, 崔韵, 牛亦农. 改良前列腺尖部分离技术保留尿道周围结构对前列腺癌根治术后即刻尿控的影响[J]. 首都医科大学学报, 2021, 42(6): 973-977.
[5]	叶小波, 熊天宇, 崔韵, 王明帅, 杨辉, 安卓玲, 牛亦农. 醋酸阿比特龙联合强的松治疗去势抵抗型前列腺癌的疗效分析[J]. 首都医科大学学报, 2021, 42(6): 978-985.
[6]	樊笑琪, 刘志斌, 王明帅, 瓦斯里江·瓦哈甫, 宋黎明, 邢念增, 牛亦农. 腹腔镜单纯尿道前壁加强法与尿道前后壁加强法(Sandwich法)改善前列腺癌根治术后早期尿控的对比分析[J]. 首都医科大学学报, 2020, 41(4): 542-546.
[7]	白志杰, 王新胜, 马洪顺, 李波. mpMRI与超声融合导航技术在前列腺靶向穿刺的临床研究[J]. 首都医科大学学报, 2020, 41(4): 631-635.
[8]	吴西抗, 王跃, 贺慧颖. 上尿路尿路上皮癌Slit引导配体3的表达与临床病理特征以及预后的关系[J]. 首都医科大学学报, 2020, 41(3): 354-359.
[9]	高巍, 赵莉红, 王玮, 王雷明, 许素素, 隗立峰, 滕梁红. 基于WHO新分类的垂体腺瘤诊断及临床病理分析[J]. 首都医科大学学报, 2020, 41(3): 364-371.
[10]	谢英伟, 金仕鹏, 李爽, 王永辉, 王伟, 平浩, 刘跃新. TMPRSS2-ERG融合基因与转移性去势抵抗性前列腺癌化学药物治疗后生存率的关系[J]. 首都医科大学学报, 2020, 41(1): 103-107.
[11]	平浩, 马林祥, 王明帅, 龙军, 牛亦农, 刘跃新, 邢念增. 单羧酸转运蛋白4(MCT4)在前列腺癌中的表达及调控研究[J]. 首都医科大学学报, 2019, 40(1): 59-64.
[12]	王蔚, 苏嘉明, 袁东波, 张伟, 陈卫红, 孙兆林, 朱建国. 微管相关蛋白1A在前列腺癌中的表达与其临床特征的关系[J]. 首都医科大学学报, 2019, 40(1): 65-71.
[13]	谢英伟, 金世鹏, 闫伟, 王伟, 平浩, 刘跃新. TMPRSS2-ERG融合基因在淋巴结转移前列腺癌中的阳性率及与生存的关系[J]. 首都医科大学学报, 2019, 40(1): 72-77.
[14]	王利娟, 阮祥燕, 赵越. PGRMC1在乳腺癌组织中的表达及其与临床病理特征的相关性[J]. 首都医科大学学报, 2018, 39(2): 272-276.
[15]	左灵坤, 阳荣辉, 马慧, 周萍, 孔璐. 生物信息学方法分析前列腺癌组织及细胞系中LMNA基因第七外显子点突变[J]. 首都医科大学学报, 2017, 38(6): 884-890.